GMAB
Genmab AS
34.80$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +134.8% | +5.2% | +384.9% | -36.1% | +30.7% | +385.1% | -65.4% | +75.6% | +88.7% | +5.3% | -84.7% | |
| – | +158.1% | +28.7% | +70.3% | +25.6% | +58.7% | +91.4% | -6.8% | +46.0% | -18.5% | +40.0% | -82.8% | |
| – | +31.9% | +45.5% | +42.9% | +19.4% | +62.0% | +36.1% | +55.0% | +41.6% | +33.5% | +23.0% | -82.2% | |
| – | – | -24,754.4% | – | -55.1% | +137.1% | +100.0% | -174.4% | – | – | – | – | |
| – | -750.1% | – | – | -334.6% | – | – | -351.6% | – | – | -217.1% | – | |
| – | +79.5% | -75.5% | +167.3% | +439.3% | -76.7% | +176.6% | -17.9% | +25.8% | +18.6% | -50.3% | -80.2% | |
| – | -52.4% | +111.0% | -34.2% | +166.3% | +11.6% | +18.6% | -59.1% | +187.3% | -53.6% | +672.8% | -43.0% | |
| – | – | – | – | – | – | +1,177.8% | +17.4% | +107.4% | – | – | – | |
| – | – | -118.4% | -100.0% | – | -93.8% | +177.8% | +1,688.0% | +103.1% | -37.9% | +607.1% | -89.2% | |
| – | – | +16,060.0% | +26,171.2% | +0.0% | +0.0% | +41.9% | +31.8% | +25.9% | -81.5% | -38.0% | +55.3% | |
| – | -37.9% | -85.8% | +135.7% | -133.0% | – | -98.1% | -691.5% | +87.9% | -23.2% | +546.7% | – | |
| – | +169.6% | -210.1% | – | -178.3% | – | +22.8% | -54.2% | -44.8% | +431.4% | -200.7% | – | |
| – | +207.6% | +67.3% | +409.3% | -64.2% | +126.1% | +404.2% | -67.7% | +81.9% | +94.8% | +8.3% | -84.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.